September 8, 2014Open Access
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Key Points
Key points are not available for this paper at this time.
Abstract
Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control. (Funded by GlaxoSmithKline; MENSA ClinicalTrials.gov number, NCT01691521.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
H
Héctor Ortega
Palo Alto Institute
M
Mark C. Liu
Union Hospital
Ian Pavord
AstraZeneca (United Kingdom)
Journals
New England Journal of Medicine
Actions
Institutions
University of Oxford
Inserm
Assistance Publique – Hôpitaux de Paris
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...